Evidence map›Paper›PMID 41100064›Full record

Trial reportThe oncologist2025

Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results.

Iben Spanggaard, Marc Matrana, Caio Rocha Lima, Amit Mahipal, Maria Vieito, Alice Hervieu, Lipika Goyal, Jordi Rodón, Maria Luisa Veronese, Natalia Oliveira and 3 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Iben SpanggaardDepartment of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen 2100, Denmark.ORCID 0000-0001-5925-2630
Marc MatranaOchsner Cancer Institute, Ochsner Clinic Foundation, New Orleans, LA 70121, United States.
Caio Rocha LimaDepartment of Hematology and Oncology, Wake Forest University School of Medicine-Atrium Health, Winston-Salem, NC 27157, United States.
Amit MahipalDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, United States.
Maria VieitoDepartment of Medical Oncology, Vall d'Hebron University Hospital, Barcelona 08035, Spain.
Alice HervieuDepartment of Medical Oncology, Centre Georges-François Leclerc, Dijon 21000, France.
Lipika GoyalMass General Cancer Center, Harvard Medical School, Boston, MA 02114, United States.
Jordi RodónMD Anderson Cancer Center, The University of Texas, Houston, TX 77030, United States.
Maria Luisa VeroneseIncyte International Biosciences Sàrl, Morges 1110, Switzerland.
Natalia OliveiraIncyte International Biosciences Sàrl, Morges 1110, Switzerland.
Xin LiIncyte Corporation, Wilmington, DE 19803, United States.
Michael SchafferIncyte Corporation, Wilmington, DE 19803, United States.
Santosh KesariProvidence Southern California Research Clinical Institute, Saint John's Cancer Institute, Pacific Neuroscience Institute, Los Angeles, CA 90404, United States.

Funding

American Academy of Neurology Annual MeetingIncyte Corporation
6 · The paper itself

Abstract

Central nervous system (CNS) tumors often harbor alterations in genes regulating key cellular pathways, including fibroblast growth factor receptor (FGFR) genes. Here, we report the efficacy and safety of treatment with pemigatinib, an oral, potent, selective FGFR1-3 inhibitor, in patients with advanced FGFR-altered CNS tumors. FIGHT-207 was a single-arm, open-label, phase 2 study of pemigatinib in patients with advanced solid tumors harboring FGFR fusions/rearrangements or other mutations. Patients received pemigatinib 13.5 mg once daily until disease progression or unacceptable toxicity. Endpoints included tumor response and safety. Of the 13 patients with CNS tumors in FIGHT-207, 10 had glioblastoma. Fibroblast growth factor receptor alterations were FGFR3-TACC3 fusions (n = 9), FGFR1 K656E mutations (n = 2), FGFR1 N546K mutation (n = 1), and FGFR1-MITF fusion (n = 1). Three patients (23%) displayed objective responses (1 complete, 2 partial). Safety was consistent with the overall FIGHT-207 population. Pemigatinib had antitumor activity and a manageable safety profile in patients with CNS tumors.

Indexed as

Central Nervous System NeoplasmsMorpholinesPyrimidinesPyrrolesReceptor, Fibroblast Growth Factor, Type 1Receptors, Fibroblast Growth FactorAdultAgedFemaleGene RearrangementHumansMaleMiddle AgedMutationReceptor, Fibroblast Growth Factor, Type 3FGFR1 protein, humanFGFR3 protein, humanMorpholinespemigatinibPyrimidinesPyrrolesReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 3Receptors, Fibroblast Growth Factorcentral nervous system tumorsfibroblast growth factor receptorsglioblastomapemigatinib

Identifiers

PMID41100064
PMCPMC12640119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.